

NIST Role in BioMetrology



Vincent L. Vilker
Chief, Biotechnology Division
NIST Visiting Committee Meeting
June 10, 2003

Overview

- Economic/Societal Areas of Impact
- Metrology Needs in Bioscience
- Current NIST Biometrology Activity
- Looking to the Future



Economic/Societal Areas of Impact

- *Health Care*
- *Food & Agrobiotechnology*
- *Biomanufacturing*
- *Homeland Security (Forensics & Biodefense)*
- *International Trade*



Areas of Impact: Health Care

➤ **Pharmaceutical**

- *Discovery*
- *Validation*

➤ **Diagnostic**

- *Reagents*
- *Devices*

➤ **Delivery & Patient Care**


- *Clinical Services*
- *Patient Information Handling*
- *Providers, Medical Plans & Insurance*



Areas of Impact: Food & Agbiotechnology

➤ *Bio-based Production*

- *Plant Crops*
- *Non-plant Therapeutics*




➤ *Bio-based Food Processing*

- *Food Production*
- *Flavors & Fragrances*

Areas of Impact: Biomanufacturing

➤ **Advanced Materials**

➤ **Reagents**



Areas of Impact: Home Land Security (Forensics & Biodefense)

➤ *Reagents*

Promega/NIST/FBI
collaborate on finding
new DNA-biomarkers

➤ *Devices*



Hand-held
immunoassay
test strips



Mission

To be the most innovative source
of biological reagents and reagent
systems used in research and applied
technology applications worldwide.



Areas of Impact: International Trade

- *In Vitro Diagnostics (IVD)*
- *Genetically Modified Crops (aka GMOs)*
- *Mycotoxin Contamination*
- *Bovine Spongiform Encephalopathy (BSE)
& *Prion-Related Diseases**




International Trade: EU IVD Directive



A New Driver:

EU IVD Directive to go into effect 2003

- Worldwide *in vitro* diagnostic device market is ~\$20B;
- **>60% of European market is supplied by U.S.**



Stated Purpose of Directive

- Eliminate trade barriers *within Europe* by ensuring access to the entire EU market with one single product approval (CE Mark)

Essential Requirements/Implementation

- IVD Calibrators and/or control materials must be traceable to **“standards of a higher order”** -- nationally/internationally recognized **certified reference materials**
- New IVD products *must* have mark by December 2003
- Existing IVD products may be sold without CE mark until December 2005

US IVD Manufacturers have requested that NIST develop internationally recognized reference methods and SRMs to meet the traceability requirement



NIST

National Institute of Standards and Technology
Technology Administration, U.S. Department of Commerce

Overview


- Economic/Societal Areas of Impact
- **Metrology Needs in Bioscience**
- Current NIST Biometrology Activity
- Looking to the Future



Metrology Needs in Bioscience

Biometrology refers to measurement and data activities that provide quantitative characterization of biology



- Gene Typing (Genomics)
- Gene Expression
- Proteins & Proteomics
- Cellular & Tissue Biology
- Bioinformatics



Metrology Needs in Bioscience


Biometrology refers to measurement and data activities that provide quantitative characterization of biology

- **Gene Typing (Genomics)**
- Gene Expression
- Proteins and Proteomics
- Cellular & Tissue Biology
- Bioinformatics



Metrology Needs in Bioscience


Gene Typing (Genotyping)



In disease diagnosis

lung cancer disease marker

150 160 170
C C C T C C C A T C C C T A C G C A T C C T T T A




Oligonucleotide Sequence Determination

Red = T

Blue = C

Green = A

Black = G



NIST Biomarker Validation Lab
Early Detection Research Network
National Cancer Institute (NIH)




NIST

National Institute of Standards and Technology
Technology Administration, U.S. Department of Commerce

Metrology Needs in Bioscience


Biometrology refers to measurement and data activities that provide quantitative characterization of biology

- Gene Typing (Genotyping)
- **Gene Expression**
- Proteins and Proteomics
- Cellular & Tissue Biology
- Bioinformatics




Metrology Needs in Bioscience

Gene Expression




Hybridization of fluorescently labeled cDNA from RNA


In disease diagnosis using gene arrays (e.g. microarrays, gene chips)



Labeled cDNA hybridizes to chip arrays – spots indicate presents of a gene, brightness indicates amount of gene product



Fluorescence Resonant Energy Transfer (FRET) indicates presence or absence of hybridized gene products




How DNA is labeled affects spot intensity!







Metrology Needs in Bioscience

Biometrology refers to measurement and data activities that provide quantitative characterization of biology

- Gene Typing (Genotyping)
- Gene Expression
- **Proteins and Proteomics**
- Cellular & Tissue Biology
- Bioinformatics




Metrology Needs in Bioscience



stem

Spec of Cellular Digest




NIST

National Institute of Standards and Technology
 Technology Administration, U.S. Department of Commerce

Metrology Needs in Bioscience

Biometrology refers to measurement and data activities that provide quantitative characterization of biology



- Gene Typing (Genotyping)
- Gene Expression
- Proteins and Proteomics
- Cellular & Tissue Biology
- Bioinformatics




Metrology Needs in Bioscience

Cellular & Tissue Biology


Imaging the morphology of smooth muscle tissue cells



Comparing stains



DNA markers of oxidative damage



Cockayne syndrome sufferers have multisystemic disorders due to a defect in the ability of cells to repair DNA that is being transcribed.




NIST

National Institute of Standards and Technology
Technology Administration, U.S. Department of Commerce

Metrology Needs in Bioscience

Biometrology refers to measurement and data activities that provide quantitative characterization of biology

- Gene Typing (Genotyping)
- Gene Expression
- Proteins and Proteomics
- Cellular & Tissue Biology
- **Bioinformatics**




Metrology Needs in Bioscience

Bioinformatics


Genotyping

Short Tandem Repeat
STRBase for
Forensics





Gene Expression

Microarrays and MIAME
Convention for preserving
pattern data



Proteins & Proteomics

Protein Data Bank



Cellular/Tissue Biology

Tissue specific biomarkers in the future.



Overview

- Economic/Societal Areas of Impact
- Metrology Needs in Bioscience
- **Current NIST Biometrology Activity**
- Looking to the Future



Current Activity: Health Care SRMs

Health Care Single Analyte SRMs

Marker

Troponin-I
Glycated Hemoglobin
Homocysteine
TSH
Speciated Iron
PSA
Folates

Under development

Trinucleotide Repeat
HER-2 neu
p53 DNA

Disease State

Myocardial Infarction
Diabetes Status
Risk of Heart Disease
Thyroid Function
Hemochromatosis
Prostate Cancer
Neural Tube Defects

Fragile X Syndrome
Breast Cancer
Breast Cancer



Current Activity: Fluorescence SRMs

- **SRM 1932 Fluorescein Solution**

- Certified for concentration and purity
- Used for fluorometer calibration
- Enables a NIST -traceable MESF fluorescence intensity scale to be established
(MESF = molecules of equivalent soluble fluorophore)



- **SRM 1933 Fluorescein Labeled Microbead Suspension**
(under development)

- To be used for flow cytometer and suspension assay calibration (MESF intensity)
- Will help meet the growing need for quantifying analyte per cell levels

Current Activity: Databases



NETWATCH

edited by Mitch Leslie

LINKS

Free Journal Finder

Plenty of online journals supply free content, and the Directory of Open Access Journals from Lund University in Sweden makes it easier to find them. The brand-new site links to more than 350 journals with free, full-text articles. You can browse titles in 15 categories, from agriculture to sociology. Scientific journals include *Stem Cells*, *Bulletin of the American Mathematical Society*, and *Conservation Ecology*. If none of the offerings catch your fancy, check back soon. The directory's curators plan to add new titles and a search feature that will allow visitors to find articles in any of the listed journals.

www.doaj.org

DATABASE

HIV's Achilles Heel

Without the enzyme protease, which chops newly manufactured viral proteins into useable strands, HIV can't replicate. Aimed at everyone from drug designers hoping to concoct more efficient blockers to students studying protein chemistry, the HIV Protease Database presents 3D structures of the crucial enzyme alone or coupling with inhibitors. Hosted by the National Institute of Standards and Technology, the collection holds measurements from more than 200 studies of HIV and SIV, the simian variant of the virus. You can search for structures by type or strain of virus, inhibitor, resolution, and other criteria, or troll a list of proteases from drug-resistant mutants. Although the database includes some info also stored in the Protein Data Bank, it also features results not available elsewhere. Above, a hydroxyethylamine inhibitor lodges in the enzyme's active site.

nldata.nist.gov/hivdb

WEB TEXT

Rewriting the Book on Biochemistry

If you're looking for an alternative to traditional beginning biochemistry texts, try this online book from chemistry professor Henry Jakubowski of the College of Saint Benedict and Saint John's University in Minnesota. The text reorganizes topics into what Jakubowski argues is a logically smoother order that eases students into the subject. For example, the book starts with lipids instead of proteins because their structure is simpler to grasp. Unlike the printed arm-breakers, it also features chemical animations and gets updated weekly.

employees.csbsju.edu/hjakubowski/classes/ch331/bcintro/default.html

unresolved copyright issues, the brew University of Jerusalem and logo did not include any of Elners, but his correspondence with pear online in the future.

tein info

end site suggestions to netwatch@aaas.org. Archive: www.sciencemag.org/netwatch

← Structural Database of HIV Protease

Science, May 30, 2003

↓ Human Mitochondrial Protein Database

Science, May 2, 2003


RESOURCES

Probing the Cell's Powerhouse

Defects in mitochondria, the cell's power plants, contribute to disorders ranging from heart degeneration to deafness to some cases of Alzheimer's disease. The Human Mitochondrial Protein Database holds a trove of information on the molecular biology of these vital organelles.

Hosted by the National Institute of Standards and Technology, the site merges info on mitochondrial protein structure and function from scattered databases, including SwissProt, GenBank, and the Neuromuscular Disease Center site. Looking for information on protein structure? The site lets you quickly search for 3D images of mitochondrial proteins, such as cytochrome c (above), from eight different species. You can parse the organelle's own DNA sequence to find out which segments code for proteins and which are edited out. Another tool lets you compare samples from more than 50 human populations from around the globe and highlight differences that can provide clues about human evolution and migration. The site also links to accounts of diseases connected to mitochondrial malfunctions.

bioinfo.nist.gov:8080/examples/servlets/index.html



www.sciencemag.org SCIENCE VOL 300 2 MAY 2003




NIST

National Institute of Standards and Technology
Technology Administration, U.S. Department of Commerce

Current Activity: Advanced Measurements


Single Molecule Measurement & Manipulation (SM³)

Single Molecule Detection Techniques:



**Combined
Fluorescence Confocal Microscopy
& Ion Current Measurements**

Simultaneous Force and Optical Measurements of Antibody/Antigen Interaction




Fluor-labeled (Alexa 488) antibody attached to a glass slide is probed with an anti-Alexa antigen attached to AFM tip.


Current Activity: Advanced Measurements

Biomaterials for Tissue Engineering



High-throughput Investigations of Cell-Material Interactions



Chemically Specific 3D Imaging of Tissue Development in Polymeric Scaffolds



Single-cell statistics



Current Activity: Assessing Needs

- *Industry* – BIO, direct interactions, ...
- *Scientific Community* – ACS, ASBMB, ABRF, IUPAC, FASEB, ACA, ASM, ...
- *Government Agencies* –NRC, FDA, CDC, NIH, NIJ, DOD, USDA, OSTP/BRWG ...
- *Standards Activities* – ASTM, NCCLS, CAP, CCQM/BIPM ...
- *Workshops* – Fluorescence, Crystallography, CASP, AFM, Proteomics, Biotech Grains, Gene Expression & Microarrays...



Current Activity: DNA Standards for Forensics

1985 First human DNA profiling system established in U.K. (RFLP)

1987 DNA evidence first successfully used in the U.S.


1991 Congress calls upon NIST to develop standards for DNA testing

Role for NIST: providing DNA standards for the forensic community – *standards will evolve with advancements in DNA typing technology*

1993 Commercial PCR based (STR) assays established

Current Activity: DNA Standards for Forensics

- SRM 2390 for RFLP-Based Profiling Standard (1992)
- SRM 2391 PCR-Based DNA Profiling Standard (1995)



- STRBase established (1997) – reference database with forensic STR info (<http://www.cstl.nist.gov/biotech/strbase/>)
- SRM 2392 Mitochondrial DNA Standard (1999)

Current Activity: DNA Standards for Forensics


- Coordinate Interlaboratory Studies to independently evaluate laboratory performance

Latest study correlating DNA quantitation accuracy to STR multiplex intensity was published May 15, 2003 in *Analytical Chemistry*

- FBI DNA Advisory Board Standards issued in 1998


Standard 9.5: “The laboratory shall check its DNA procedures annually or whenever substantial changes are made to the protocol(s) against an appropriate and available NIST Standard Reference Material or standard traceable to a NIST standard.”

- Member of FBI’s Scientific Working Group on DNA Analysis Methods (SWGDM) — help set validation guidelines and establish core loci for national forensic database



Current Activity: DNA Standards for Forensics

- Development of miniSTRs for more sensitive STR typing: used for typing highly degraded WTC samples



- Evaluation of Y chromosome SNPs and STRs to enable selection of optimal loci for human identification
- Y chromosome DNA profiling standard (SRM 2395) completed May 2003 to enable growing forensic, paternity, and genetic genealogy use of Y chromosome
- Human DNA quantification standard(SRM 2372) under development

Current Activity: Gene Expression

Oct 2002 – NIST Meeting on Metrology and Standards for Gene Expression Technologies (Device Makers, Technology Users, Regulators)

Dec 2002 – NIST/Industry Workshop on Standards Needs for Microarrays (Device Makers)

**March 2003 – NIST/Industry Workshop on Universal RNA Standards held at Stanford University (Device Makers, Reagent Makers, Technology Users, Regulators)
100 folks attended, 33 companies, FDA, CDC, NIH/NCI, NIH/NIEHS, 4 Universities**



Current Activity: Gene Expression

Workshop on Universal RNA Standards Stanford University: Goals

- **Identify key measurement & data issues facing technology**
 - *short- and long-term*
- **Will all platforms (microarray only? or bioarrays?) benefit from identified issues**
- **Identify issues that belong to NIST (*applied biology*) or NIH (*discovery biology*)**
 - *differences*
- **Can issues be resolved without NIST**
 - *why & why not (pros & cons)*
- **Should NIST resolve these issues**
 - *define role NIST should take*
 - *identify partnerships with NIST to address issues*
- **Will microarrays require FDA approval for P.O.C. and diagnostic market**
 - *identify industry (research and diagnostic) consequences of not addressing issues of metrology*



NIST

National Institute of Standards and Technology
Technology Administration, U.S. Department of Commerce

Current Activity: Gene Expression

Workshop Outcomes: Standards Activities
(what can we do, what should we not do)


- Disease Specific Devices/Reagents
 - Tied to IP, and therefore \$\$
 - Calibration should be part of the investment in technology development
 - No role for NIST
- Toxicogenomics
 - Role for NIST where platform and/or reagents will be used for a long time
 - Partner with FDA to define standards needs
- Data Transferability (over location, time)
 - One platform at a time, comment on life expectancy of platform
 - FDA/Industry consensus
 - NIST role in Phase 2
- Standard for Evaluating Lab Proficiency
 - Specific request directed to NIST by FDA



Current Activity: Gene Expression

➤ Microarray Slide SRM – 6 Device Makers

- Size (active area, background area, placement)
- Accommodation 1x3 and Affy format
- Barcode
- Thickness
- Non-parallelism tolerance
- Fiducial type and placement



➤ Standard for Quantitative PCR

- Cross platform, unrelated to any known gene
- First CCQM project, in collaboration with LGC, Ltd

➤ Particle Fluorescence SRM 1933

➤ Research on FRET

➤ Research on Non-Canonical RNA Structures

Overview

- Economic/Societal Areas of Impact
- Metrology Needs in Bioscience
- Current NIST Biometrology Activity
- Looking to the Future



NIST


National Institute of Standards and Technology
Technology Administration, U.S. Department of Commerce

Biology at NIST: 20 years of Context

- **NIST Base Programmatic Investment**
.....Competence in Biotechnology 1981, CARB MOU 1983,
- **External (Stakeholder) Investment**
.....NIH/RO1 Grant to CARB since 1987, NIJ 1993, NSF/DOE/NIH for PDB 1998,.....
- **ATP Intramural Investment**
.....DNA Technologies 1993, Biocatalysis 1996,





Biology at NIST: 20 years of Context



$$\Delta G^{\circ} = f(\text{Temperature})$$

↑ Yield = ↑ \$



1st Biotech Competence
CARB MOU

CARB Building
Biotech Division

NIJ/NIST DNA SRMs

PDB at NIST
NCI establish EDRN
SM³ & TE

NIST/NIH Directors Meet
NIST/NIH Postdoc Program



1980

1985

1990

1995

2000

2005

2010



NIST

National Institute of Standards and Technology
Technology Administration, U.S. Department of Commerce

Looking to the future...

Special Report

“First, they will have to go beyond narrowly studying one gene at a time and start probing the complicated interplay of genes and proteins along a disease's entire cellular pathway. That will require unprecedented cooperation across a range of sciences.”

— *Business Week*, June 2, 2003

The science is hot and the stocks are up. Here's what's needed to deliver on the promise

BY ARLENE WEINTRAUB

Genentech's experimental colon cancer drug, Avastin, is anything but an overnight success. Thirteen years ago, one of its scientists found a gene that regulates blood flow to tumors, and started looking for a way to turn it off. It took the company five years to develop an antibody that could act as a switch in mice, and another three to fashion it into a drug. Then came animal tests, safety tests, and large-scale human trials to gauge the drug's effectiveness. And with every progress report, good and bad, Wall Street responded by pumping or pummeling the company's shares.

Right now, the pump is on. On May 19, Genentech Inc. announced that Avastin extends patients' lives when given with chemotherapy, raising hopes that it will be the first of a new class of drugs that can choke off the supply of blood to tumors. Investors pushed Genentech's stock up 45%, to \$55, on the news. The trials aren't complete, and government approval isn't guaranteed, but Genentech is sanguine. “We're finding fundamentally different ways of treating people who are suffering and desperate,” says Genentech Chief Medical Officer Dr. Susan Desmond-Hellmann.

Desmond-Hellmann's optimism and her company's struggles with Avastin mirror the experiences of biotech execs everywhere. Scientifically, the industry has reached a watershed: The human genome has been sequenced, as have the genomes of some microbes and animals. Every day, scientists learn more about the intricate molecular dance of life and how the process runs wild in disease. The technology to transform these discoveries into life-saving therapies also is advancing quickly.

The medical and commercial rewards in biotech are now abundantly clear. While it will take months for Avastin to reach the market, analysts believe it could eventually pull in more than \$1 billion a year. That would add nicely to the industry's revenue stream,

**FIVE
HURDLES
FOR**

**BIO
TECH**

Looking to the future...

Special Report

- Gene Expression
- Proteomics
- NanoBiotechnology
- DNA and Protein Markers

"The idea is to look at larger, more global questions, and understand the coordinating activities of genes, cells, and organs."

— Ronald M. Evans, Salk Institute

The science is hot and the stocks are up. Here's what's needed to deliver on the promise

BY ARLENE WEINTRAUB

Genentech's experimental colon cancer drug, Avastin, is anything but an overnight success. Thirteen years ago, one of its scientists found a gene that regulates blood flow to tumors, and started looking for a way to turn it off. It took the company five years to develop an antibody that could act as a switch in mice, and another three to fashion it into a drug. Then came animal tests, safety tests, and large-scale human trials to gauge the drug's effectiveness. And with every progress report, good and bad, Wall Street responded by pumping or punning the company's shares.

Right now, the pump is on. On May 19, Genentech Inc. announced that Avastin extends patients' lives when given with chemotherapy, ruling hopes that it will be the first of a new class of drugs that cut choke off the supply of blood to tumors. Investors pushed Genentech's stock up 15% to \$46 on the news. The trials aren't complete, and government approval isn't guaranteed, but Genentech is sanguine. "We're finding fundamentally different ways of treating people who are suffering and desperate," says Genentech Chief Medical Officer Dr. Susan Desmaretz-Hellmann.

Desmaretz-Hellmann's optimism and her company's struggles with Avastin mirror the experience of biotech execs everywhere. Scientifically, the industry has reached a watershed: The human genome has been sequenced, so have the genomes of some microbes and animals. Every day, when

lists learn more about the intricate molecular dance of life and how the process runs wild in disease. The technology to transform those discoveries into life-saving therapies also is advancing quickly.

The medical and commercial rewards in biotech are vast and abundant. While it will take months for Avastin to reach the market, analysts believe it could eventually pull in more than \$1 billion a year. That would add nicely to the industry's revenue stream.

**FIVE
HURDLES
FOR**

**BIO
TECH**